肠杆菌属细菌的临床分布及耐药特性分析  

Clinical distribution and antibiotic resistance analysis of Enterobacter spp

作　　者：李宗良[1] 赖春颜[1] 梁敏锋[1] 马均宝[1] 

机构地区：[1]佛山市第一人民医院感染科,广东省528000

出　　处：《中国实用医药》2014年第17期3-5,共3页China Practical Medicine

摘　　要：目的：了解肠杆菌属细菌的临床分布和耐药状况，为临床治疗提供依据。方法采用法国生物梅里埃公司VITEK-2型全自动细菌分析系统，配合GN鉴定卡和AST-GN13药敏检测卡对细菌进行鉴定和药敏试验，应用Whonet5.5软件进行统计分析。结果506株肠杆菌属细菌中阴沟肠杆菌占78.3%、产气肠杆菌占16.8%。标本主要来自痰267株（52.8%）、创面69株（13.6%）、尿液53株（10.5%）、血液47株（9.3%）。肠杆菌属细菌对头孢唑啉、头孢西丁、氨苄西林、头孢替坦、氨苄西林/舒巴坦耐药率最高，均高于95%，对头孢吡肟、厄他培南、左氧氟沙星、头孢哌酮/舒巴坦、美洛培南耐药率较低，均在5%-10%，对亚胺培南、阿米卡星耐药率最低，分别为0.8%和3.0%。结论肠杆菌属细菌对抗菌药物的耐药情况严重，临床应根据药敏结果合理使用抗菌药物。Objective To explore the clinical distribution and antibiotic resistance of Enterobacter spp, to provide the evidence for clinical treatment. Methods The bacterial identification and antimicrobial susceptibility testing were performed by using the GN identification card and AST-GN13 susceptibility testing card of VITEK2-Compact automatic instrument from French Bio-Merieux. The statistical analysis was performed with Whonet 5.5 software. Results Enterobacter cloacae and Enterobacter aerogenes accounted for 78.3%and 16.8%out of the 506 Enterobacter spp, respectively.The major source of specimens were from sputum 267（52.8%）, wounds69（13.6%）, urinary53（10.5%）and blood 47（9.3%）. The Enterobacter spp showed the highest resistance rate to ampicillin, cefoxitin, cefozolin, cefotetan, ampicillin/sulbactam （〉95%）, and relatively lower resistance rate to meropenem, levofloxacin, cefepime, ertapenem, cefoperazone/sulbactam （generally between 5%and 10%）, and the lowest resistance rate to imipenem and amikacin （0.8%and 3.0%, respectively）. Conclusion Antibiotic resistance of Enterobacter spp is serious, clinical treatment should be rational according to susceptibility test Results.

关 键 词：肠杆菌属 阴沟肠杆菌 产气肠杆菌 耐药性 

分 类 号：R446.5[医药卫生—诊断学]